Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Philis-Tsimikas

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
The Journal of Ambulatory Care Management|February 24, 2001
Improved care for diabetes in underserved populationsA Philis-Tsimikas, C Walker
Arteriosclerosis, Thrombosis, and Vascular Biology|March 1, 1995
Aminoguanidine has both pro-oxidant and antioxidant activity toward LDLA Philis-Tsimikas, S Parthasarathy, S Picard, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 15, 1999
LDL isolated from Greek subjects on a typical diet or from American subjects on an oleate-supplemented diet induces less monocyte chemotaxis and adhesion when exposed to oxidative stressS Tsimikas, A Philis-Tsimikas, S Alexopoulos, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|August 20, 2013
Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trialH W Rodbard, B Cariou, B Zinman, et al.
Diabetes, Obesity & Metabolism|January 22, 2014
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)C Mathieu, H W Rodbard, B Cariou, et al.
Diabetes, Obesity & Metabolism|April 13, 2013
Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agentsA Philis-Tsimikas, S Del Prato, I Satman, et al.
Diabetes Research and Clinical Practice|November 19, 2018
Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitusA Philis-Tsimikas, K Astamirova, Y Gupta, et al.
Diabetes, Obesity & Metabolism|March 19, 2016
Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study)V R Aroda, T S Bailey, B Cariou, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
The Journal of Ambulatory Care Management|February 24, 2001
Improved care for diabetes in underserved populationsA Philis-Tsimikas, C Walker
Arteriosclerosis, Thrombosis, and Vascular Biology|March 1, 1995
Aminoguanidine has both pro-oxidant and antioxidant activity toward LDLA Philis-Tsimikas, S Parthasarathy, S Picard, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 15, 1999
LDL isolated from Greek subjects on a typical diet or from American subjects on an oleate-supplemented diet induces less monocyte chemotaxis and adhesion when exposed to oxidative stressS Tsimikas, A Philis-Tsimikas, S Alexopoulos, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|August 20, 2013
Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trialH W Rodbard, B Cariou, B Zinman, et al.
Diabetes, Obesity & Metabolism|January 22, 2014
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)C Mathieu, H W Rodbard, B Cariou, et al.
Diabetes, Obesity & Metabolism|April 13, 2013
Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agentsA Philis-Tsimikas, S Del Prato, I Satman, et al.
Diabetes Research and Clinical Practice|November 19, 2018
Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitusA Philis-Tsimikas, K Astamirova, Y Gupta, et al.
Diabetes, Obesity & Metabolism|March 19, 2016
Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study)V R Aroda, T S Bailey, B Cariou, et al.
Pageof 1